Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
FDA Official Rebuts Patient Advocates’ Biosimilar ConcernsInsideHealthPolicy.com's FDA Week, 2018-09, Vol.24 (37), p.5-6Copyright Inside Washington Publishers Sep 14, 2018 ;ISSN: 2165-4166Full text available |
|
2 |
Material Type: Article
|
CMS PROPOSES TO LET RX PLANS USE NON-INTERCHANGEABLE BIOSIMILARSInsideHealthPolicy.com's FDA Week, 2023-11, Vol.29 (45)Copyright Inside Washington Publishers Nov 10, 2023 ;ISSN: 2165-4166Full text available |
|
3 |
Material Type: Article
|
FDA REMOTE EVALUATIONS VOLUNTARY, BUT DECLINING COULD DELAY REG ACTIONInsideHealthPolicy.com's FDA Week, 2023-11, Vol.29 (44)Copyright Inside Washington Publishers Nov 3, 2023 ;ISSN: 2165-4166Full text available |
|
4 |
Material Type: Article
|
MODERNA IS FIRST TO SEEK FDA AUTHORIZATION FOR XBB.1.5 COVID VAXInsideHealthPolicy.com's FDA Week, 2023-06, Vol.29 (26)Copyright Inside Washington Publishers Jun 30, 2023 ;ISSN: 2165-4166Full text available |
|
5 |
Material Type: Article
|
FDA SELECTS XBB.1.5 AS TARGET FOR FALL COVID VAX ROLLOUTInsideHealthPolicy.com's FDA Week, 2023-06, Vol.29 (25)Copyright Inside Washington Publishers Jun 23, 2023 ;ISSN: 2165-4166Full text available |
|
6 |
Material Type: Article
|
FDA: GENERAL SCIENTIFIC KNOWLEDGE CAN SUPPORT, SPEED DRUG APPROVALSInsideHealthPolicy.com's FDA Week, 2023-06, Vol.29 (22)Copyright Inside Washington Publishers Jun 2, 2023 ;ISSN: 2165-4166Full text available |
|
7 |
Material Type: Article
|
FDA GUIDE THAT MAY OPEN PATH TO BRANDED BIOSIMILARS CLEARS OMBInsideHealthPolicy.com's FDA Week, 2020-03, Vol.26 (10)Copyright Inside Washington Publishers Mar 6, 2020 ;ISSN: 2165-4166Full text available |
|
8 |
Material Type: Article
|
OMB REVIEWING BIOLOGICS GUIDE THAT MIGHT LEAD TO BRANDED BIOSIMILARSInsideHealthPolicy.com's FDA Week, 2020-02, Vol.26 (9)Copyright Inside Washington Publishers Feb 28, 2020 ;ISSN: 2165-4166Full text available |
|
9 |
Material Type: Article
|
WHO Unveils Final Biological Naming Plan That Differs From FDA’sInsideHealthPolicy.com's FDA Week, 2016-01, Vol.22 (4), p.1-11Copyright Inside Washington Publishers Jan 29, 2016 ;ISSN: 2165-4166Full text available |
|
10 |
Material Type: Article
|
FDA Backtracks On Contentious Interchangeability Study RequirementInsideHealthPolicy.com's FDA Week, 2018-07, Vol.24 (29), p.8-8Copyright Inside Washington Publishers Jul 20, 2018 ;ISSN: 2165-4166Full text available |
|
11 |
Material Type: Article
|
BIPARTISAN SENATE BILL WOULD SPEED INTERCHANGEABLE BIOSIMILAR COMPETITIONInsideHealthPolicy.com's FDA Week, 2022-05, Vol.28 (21)Copyright Inside Washington Publishers May 27, 2022 ;ISSN: 2165-4166Full text available |
|
12 |
Material Type: Article
|
CDER OFFICIAL URGES BIOSIMILARS MAKERS TO FOCUS ON QUALITYInsideHealthPolicy.com's FDA Week, 2023-11, Vol.29 (44)Copyright Inside Washington Publishers Nov 3, 2023 ;ISSN: 2165-4166Full text available |
|
13 |
Material Type: Article
|
REGULATORY AGENDA INCLUDES 340B, BIOSIMILAR, OTC DRUG MEASURESInsideHealthPolicy.com's FDA Week, 2021-12, Vol.27 (50)Copyright Inside Washington Publishers Dec 17, 2021 ;ISSN: 2165-4166Full text available |
|
14 |
Material Type: Article
|
FDA ADVISERS RECOMMEND MONOVALENT XBB COVID VAX FOR FALLInsideHealthPolicy.com's FDA Week, 2023-06, Vol.29 (25)Copyright Inside Washington Publishers Jun 23, 2023 ;ISSN: 2165-4166Full text available |
|
15 |
Material Type: Article
|
FDA REVISES DRAFT GUIDE WITH DETAILS ON ADJUSTING FOR COVARIATES IN TRIALSInsideHealthPolicy.com's FDA Week, 2021-05, Vol.27 (21)Copyright Inside Washington Publishers May 28, 2021 ;ISSN: 2165-4166Full text available |
|
16 |
Material Type: Article
|
FDA: DON'T IMPLY REFERENCE DRUGS, INTERCHANGEABLES BETTER THAN BIOSIMSInsideHealthPolicy.com's FDA Week, 2024-04, Vol.30 (17)Copyright Inside Washington Publishers Apr 26, 2024 ;ISSN: 2165-4166Full text available |
|
17 |
Material Type: Article
|
ASBM Uses European Biosimilar Naming Survey To Push Unique NamesInsideHealthPolicy.com's FDA Week, 2013-11, Vol.19 (48), p.2-2Copyright Inside Washington Publishers Nov 27, 2013 ;ISSN: 2165-4166Full text available |
|
18 |
Material Type: Article
|
SENATE PARLIAMENTARIAN AXES COMMERCIAL INFLATION CAPSInsideHealthPolicy.com's FDA Week, 2022-08, Vol.28 (32)Copyright Inside Washington Publishers Aug 12, 2022 ;ISSN: 2165-4166Full text available |
|
19 |
Material Type: Article
|
PRESIDENT'S BUDGET CALLS FOR UNRESTRICTED BIOSIMILAR SWITCHINGInsideHealthPolicy.com's FDA Week, 2024-03, Vol.30 (11)Copyright Inside Washington Publishers Mar 15, 2024 ;ISSN: 2165-4166Full text available |
|
20 |
Material Type: Article
|
COHERUS: FAVORED-NATION DEMO UNDERMINES BIOSIMILARSInsideHealthPolicy.com's FDA Week, 2020-12, Vol.26 (49)Copyright Inside Washington Publishers Dec 4, 2020 ;ISSN: 2165-4166Full text available |